

WHO/CDS/WHOPES/GCDPP/2005.13

GUIDELINES FOR LABORATORY AND FIELD TESTING OF MOSQUITO LARVICIDES



**WORLD HEALTH ORGANIZATION
COMMUNICABLE DISEASE CONTROL, PREVENTION
AND ERADICATION
WHO PESTICIDE EVALUATION SCHEME**

© World Health Organization 2005

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

CONTENTS

	Page
ACKNOWLEDGEMENTS	3
1. INTRODUCTION	5
2. PHASE I: LABORATORY STUDIES	7
2.1 Determination of biological activity	8
2.1.1 Larvicides other than bacterial products and insect growth regulators	8
2.1.2 Insect growth regulators	12
2.1.3 Bacterial larvicides	14
2.2 Determination of the diagnostic concentration	19
2.3 Cross-resistance assessment	19
3. PHASE II: SMALL-SCALE FIELD TRIALS	20
3.1 Trials in natural breeding sites	21
3.1.1 Data analysis	24
3.2 Simulated field trials	24
3.2.1 Data analysis	26
3.3 Selection of optimum field application dosage	27
4. PHASE III: LARGE-SCALE FIELD TRIALS	27
4.1 Selection of study sites	28
4.2 Assessment of pretreatment density	28
4.3 Application of larvicide	29

4.4	Assessment of post-treatment density	29
4.5	Effect on non-target organisms	29
4.6	Operational and community acceptability	30
4.7	Data analysis	30
REFERENCES		31
ANNEX 1		
PRODUCTION OF TEST LARVAE		32
ANNEX 2		
DILUTIONS AND CONCENTRATIONS		34
ANNEX 3		
MEASUREMENTS AND CONVERSIONS		35
ANNEX 4		
DATA RECORDING FORMS		36

ACKNOWLEDGEMENTS

The Department of Communicable Disease Control, Prevention and Eradication (CPE) wishes to thank Dr P. Jambulingam, Vector Control Research Centre, Pondicherry, India, for drafting this document.

CPE also wishes to thank the following for their valuable contribution to the development of this document.

Dr M.K. Cham, Roll Back Malaria Department, World Health Organization, Geneva, Switzerland.

Dr V. Corbel, Institut de recherche pour le développement (IRD), Montpellier, France.

Dr P. Guillet, WHO Regional Office for Africa, Harare, Zimbabwe.

Dr H. Ladonni, Department of Medical Entomology and Vector Control, School of Public Health, Tehran University of Medical Sciences, Tehran, the Islamic Republic of Iran.

Dr C. Lagneau, Entente interdépartementale pour la démoustication du littoral méditerranéen, Montpellier, France.

Dr H.H. Lee, Institute for Medical Research, Kuala Lumpur, Malaysia.

Dr L. Manga, WHO Regional Office for Africa, Harare, Zimbabwe.

Dr M. Mazzarri, Division of Control of Vectors, Ministry of Health, Maracay, Venezuela.

Dr M.S. Mulla, Department of Entomology, University of California, Riverside, California, USA.

Dr S. Nalim, National Institute for Vector Control Research, Salatiga, Central Java, Indonesia.

Dr M. Nathan, Department of Communicable Disease Control, Prevention and Eradication, World Health Organization, Geneva, Switzerland.

Dr S.N. Sharma, National Institute of Communicable Diseases, Delhi, India.

Dr E. Walker, Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA.

Dr M. Zaim, WHO Pesticide Evaluation Scheme (WHOPES), Department of Communicable Disease Control, Prevention and Eradication, World Health Organization, Geneva, Switzerland.

This publication has been funded by the Global Collaboration for Development of Pesticides for Public Health (GCDPP).

1. INTRODUCTION

The purpose of this document is to provide specific and standardized procedures and guidelines for testing larvicides, including bacterial larvicides and insect growth regulators (IGRs), against mosquitoes. Its aim is to harmonize the testing procedures carried out in different laboratories and institutions to generate data for the registration and labelling of larvicides by national authorities.

The document is an expanded and updated version of the guidelines recommended by the WHO Pesticide Evaluation Scheme (WHOPES) Informal Consultation on the evaluation and testing of insecticides, held at WHO headquarters (HQ), Geneva, 7–11 October 1996 (1). The guidelines were reviewed and recommended by the Eighth WHOPES Working Group Meeting, held at WHO-HQ, Geneva, 1–3 December 2004 (2).

The document provides guidance on laboratory studies and small-scale and large-scale field trials to determine the efficacy, field application rates and operational feasibility and acceptability of a mosquito larvicide. The table below summarizes the sequence and objectives of the studies and trials. The procedures provide some information on the safety and toxicity of the larvicides for non-target organisms, but it is presumed that preliminary eco-toxicity and human assessments have been undertaken before any field study is carried out – detailed treatment and analysis of these extra data are beyond the scope of this document.

Table 1.1
Sequence of the stages of evaluation of mosquito larvicides

Phase	Type of study	Aim
Phase I	Laboratory studies	<ul style="list-style-type: none">• Biopotency and activity• Diagnostic concentration and assessment of cross-resistance
Phase II	Small-scale field trials	<ul style="list-style-type: none">• Efficacy under different ecological settings• Method and rate of application• Initial and residual activity• Effect on non-target organisms
Phase III	Large-scale field trials	<ul style="list-style-type: none">• Efficacy and residual activity• Operational and community acceptance• Effect on non-target organisms

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_29919

